

Ansell Healthcare (Europe) N.V

Riverside Business Park – Block J
Boulevard International 55
1070 Brussels, Belgium

T. + 32 (0)2 528 74 00
F. + 32 (0)2 528 74 00
www.ansell.com



Ansell is fully committed to its obligations as per European Regulation 1907/2006 and its amendments, concerning the Registration, Evaluation, Authorisation and Restrictions of Chemicals.

All Ansell currently produced products comply to the requirements of Annex XVII (including relevant amendments) related to the 'restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles'.

With respect to the Candidate list with "Substances of very high concern (SVHC) for Authorization", published by the European Chemicals Agency (ECHA) and last amended on 10 June 2022; and as required by Article 33 of the REACH Regulation, we confirm that our articles, currently manufactured for the EU-EMEA markets do not contain SVHC substances in excess of 0.1% weight by weight.

A handwritten signature in blue ink, appearing to read "Derek Warneke". The signature is fluid and cursive, with the first letter of each word being significantly larger and more stylized than the others.

Derek Warneke VP QARA,

HGBU Ansell Healthcare

26 July 2022